260 related articles for article (PubMed ID: 23237198)
1. H-gemcitabine: a new gemcitabine prodrug for treating cancer.
Dasari M; Acharya AP; Kim D; Lee S; Lee S; Rhea J; Molinaro R; Murthy N
Bioconjug Chem; 2013 Jan; 24(1):4-8. PubMed ID: 23237198
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of oral prodrugs based on the structure of gemcitabine.
Zhao C; Xue X; Li G; Sun C; Sun C; Qu X; Li W
Chem Biol Drug Des; 2012 Sep; 80(3):479-88. PubMed ID: 22642666
[TBL] [Abstract][Full Text] [Related]
3. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs.
Immordino ML; Brusa P; Rocco F; Arpicco S; Ceruti M; Cattel L
J Control Release; 2004 Dec; 100(3):331-46. PubMed ID: 15567500
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine-based therapy for pancreatic cancer using the squalenoyl nucleoside monophosphate nanoassemblies.
Maksimenko A; Caron J; Mougin J; Desmaële D; Couvreur P
Int J Pharm; 2015 Mar; 482(1-2):38-46. PubMed ID: 25448549
[TBL] [Abstract][Full Text] [Related]
5. Multifunctional Tumor-Targeting Cathepsin B-Sensitive Gemcitabine Prodrug Covalently Targets Albumin in Situ and Improves Cancer Therapy.
Zhang H; Sun Z; Wang K; Li N; Chen H; Tan X; Li L; He Z; Sun J
Bioconjug Chem; 2018 Jun; 29(6):1852-1858. PubMed ID: 29775284
[TBL] [Abstract][Full Text] [Related]
6. Polyisoprenoyl gemcitabine conjugates self assemble as nanoparticles, useful for cancer therapy.
Maksimenko A; Mougin J; Mura S; Sliwinski E; Lepeltier E; Bourgaux C; Lepêtre S; Zouhiri F; Desmaële D; Couvreur P
Cancer Lett; 2013 Jul; 334(2):346-53. PubMed ID: 22935679
[TBL] [Abstract][Full Text] [Related]
7. Capecitabine in carcinoma of the pancreas.
Smith DB; Neoptolemos JP
Expert Opin Pharmacother; 2006 Aug; 7(12):1633-9. PubMed ID: 16872266
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of gemcitabine and its amino acid ester prodrug following intravenous and oral administrations in mice.
Thompson BR; Shi J; Zhu HJ; Smith DE
Biochem Pharmacol; 2020 Oct; 180():114127. PubMed ID: 32603666
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs.
Brusa P; Immordino ML; Rocco F; Cattel L
Anticancer Res; 2007; 27(1A):195-9. PubMed ID: 17352232
[TBL] [Abstract][Full Text] [Related]
10. Combination of l-Carnitine with Lipophilic Linkage-Donating Gemcitabine Derivatives as Intestinal Novel Organic Cation Transporter 2-Targeting Oral Prodrugs.
Wang G; Chen H; Zhao D; Ding D; Sun M; Kou L; Luo C; Zhang D; Yi X; Dong J; Wang J; Liu X; He Z; Sun J
J Med Chem; 2017 Mar; 60(6):2552-2561. PubMed ID: 28234466
[TBL] [Abstract][Full Text] [Related]
11. Enhanced Antitumor Activity of Monophosphate Ester Prodrugs of Gemcitabine: In Vitro and In Vivo Evaluation.
Qi H; Lu J; Li J; Wang M; Xu Y; Wang Y; Zhang H
J Pharm Sci; 2016 Sep; 105(9):2966-2973. PubMed ID: 26994559
[TBL] [Abstract][Full Text] [Related]
12. Interaction of an amphiphilic squalenoyl prodrug of gemcitabine with cellular membranes.
Bildstein L; Pili B; Marsaud V; Wack S; Meneau F; Lepêtre-Mouelhi S; Desmaële D; Bourgaux C; Couvreur P; Dubernet C
Eur J Pharm Biopharm; 2011 Nov; 79(3):612-20. PubMed ID: 21784150
[TBL] [Abstract][Full Text] [Related]
13. Multifunctional squalene-based prodrug nanoparticles for targeted cancer therapy.
Bui DT; Nicolas J; Maksimenko A; Desmaële D; Couvreur P
Chem Commun (Camb); 2014 May; 50(40):5336-8. PubMed ID: 24185552
[TBL] [Abstract][Full Text] [Related]
14. A facile di-acid mono-amidation strategy to prepare cyclization-activating mono-carboxylate transporter 1-targeting gemcitabine prodrugs for enhanced oral delivery.
Wang Y; Wang G; Chen H; Sun Y; Sun M; Liu X; Jian W; He Z; Sun J
Int J Pharm; 2020 Jan; 573():118718. PubMed ID: 31756441
[TBL] [Abstract][Full Text] [Related]
15. Diels Alder-mediated release of gemcitabine from hybrid nanoparticles for enhanced pancreatic cancer therapy.
Oluwasanmi A; Al-Shakarchi W; Manzur A; Aldebasi MH; Elsini RS; Albusair MK; Haxton KJ; Curtis ADM; Hoskins C
J Control Release; 2017 Nov; 266():355-364. PubMed ID: 28943195
[TBL] [Abstract][Full Text] [Related]
16. Thermosensitive polymer prodrug nanoparticles prepared by an all-aqueous nanoprecipitation process and application to combination therapy.
Guerassimoff L; Ferrere M; Van Herck S; Dehissi S; Nicolas V; De Geest BG; Nicolas J
J Control Release; 2024 May; 369():376-393. PubMed ID: 38554772
[TBL] [Abstract][Full Text] [Related]
17. Antitumoral activity of PEG-gemcitabine prodrugs targeted by folic acid.
Pasut G; Canal F; Dalla Via L; Arpicco S; Veronese FM; Schiavon O
J Control Release; 2008 May; 127(3):239-48. PubMed ID: 18346806
[TBL] [Abstract][Full Text] [Related]
18. Synergistic targeting/prodrug strategies for intravesical drug delivery--lectin-modified PLGA microparticles enhance cytotoxicity of stearoyl gemcitabine by contact-dependent transfer.
Neutsch L; Wirth EM; Spijker S; Pichl C; Kählig H; Gabor F; Wirth M
J Control Release; 2013 Jul; 169(1-2):62-72. PubMed ID: 23588390
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine-coumarin-biotin conjugates: a target specific theranostic anticancer prodrug.
Maiti S; Park N; Han JH; Jeon HM; Lee JH; Bhuniya S; Kang C; Kim JS
J Am Chem Soc; 2013 Mar; 135(11):4567-72. PubMed ID: 23461361
[TBL] [Abstract][Full Text] [Related]
20. An insight into potential of nanoparticles-assisted chemotherapy of cancer using gemcitabine and its fatty acid prodrug:a comparative study.
Gupta A; Asthana S; Konwar R; Chourasia MK
J Biomed Nanotechnol; 2013 May; 9(5):915-25. PubMed ID: 23802424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
